Alkem Laboratories Ltd. , a prominent Indian pharmaceutical company, has announced significant business restructuring and reported robust financial results for the first quarter, while also facing regulatory challenges.

Business Transfer Agreement

Alkem Laboratories has entered into a business transfer agreement with its wholly-owned subsidiary, Alkem Wellness Limited. According to the company's disclosure under SEBI LODR Regulations, the transfer of the trade generics business will be effective from October 1, 2025. This move, initially announced in December 2024, involves transferring the business as a going concern on a slump sale basis.

Strong Q1 FY2026 Performance

For the April-June quarter of FY2026, Alkem Laboratories demonstrated impressive financial results:

The company's performance was driven by a 2.9% overall volume growth, showcasing its resilience in the pharmaceutical market.

GST Order and Company's Response

Alkem Laboratories faces a regulatory challenge as it received a GST order confirming a demand of ₹35.11 crore, along with a penalty of ₹3.50 crore. The order covers the period from July 2017-18 to March 2022 and primarily alleges denial of input tax credit due to double claims. However, the company has expressed disagreement with the order and intends to contest it, demonstrating its commitment to resolving regulatory issues.

Market Response

Despite the strong quarterly results, Alkem Laboratories' shares ended lower by 1.72% at ₹5,413.50, possibly reflecting investor concerns over the GST order.

The company's strategic move to transfer its trade generics business to a wholly-owned subsidiary, coupled with its strong financial performance, indicates Alkem's efforts to optimize its business structure and maintain growth momentum. However, the ongoing GST dispute adds a layer of complexity to the company's regulatory landscape, which investors will likely monitor closely in the coming months.

Alkem Laboratories has made headlines with two significant developments: a GST demand and the launch of a breakthrough cancer treatment.

GST Demand and Penalty

Alkem Laboratories has received a GST appeal order demanding Rs. 35.11 crore along with a penalty of Rs. 3.51 crore. The pharmaceutical company has announced its intention to contest this order, signaling a potential legal challenge ahead.

Innovative Treatment for HER2-Positive Breast Cancer

In a separate development, Alkem has launched Pertuza, a pertuzumab biosimilar, for HER2-positive breast cancer in India. This marks a crucial step towards improving accessibility and affordability of advanced cancer treatments in the country.

Pertuza, an injection of 420mg/14mL, is an indigenously-developed and manufactured biosimilar of pertuzumab. The drug has demonstrated equivalence in efficacy, safety, and immunogenicity to the reference product in a pivotal phase 3 clinical trial conducted by Alkem's biotech subsidiary.

Addressing Accessibility Challenges

Dr. Vikas Gupta, Chief Executive Officer of Alkem, emphasized the importance of this launch, stating, "Breast cancer is the most common cancer among Indian women, and addressing its growing burden requires treatments that are effective, accessible and affordable." The company aims to make this critical therapy available to thousands of women each year who would otherwise be excluded due to cost barriers.

Strengthening Oncology Portfolio

The introduction of Pertuza further solidifies Alkem's position in the oncology sector. The company's growing portfolio includes other key products such as:

• Cetuximab biosimilar
• Denosumab biosimilar
• Bevacizumab biosimilar
• Romiplostim biosimilar

About Alkem Laboratories

Alkem Laboratories, with a 50-year legacy, stands as the fifth largest pharmaceutical company in the Indian market. The company boasts:

• 19 state-of-the-art manufacturing facilities
• Cutting-edge research and development (R&D) centers across India and the US
• A strong presence in therapy areas including anti-infectives, gastrointestinal, pain management drugs, and supplements
• A growing portfolio in chronic therapies such as diabetes, neurology, cardiology, dermatology, and urology

With the motto "Inspiring Healthier Lives," Alkem continues to reinforce its commitment to global health improvement through innovative and accessible medical solutions.

Financial Performance

In its latest quarterly results, Alkem Laboratories reported strong financial performance:

Despite the positive results, the company's shares ended 1% lower at ₹5,486.00 on the NSE.

The launch of Pertuza represents a significant step forward in Alkem's mission to combine scientific excellence with wider access to critical therapies, potentially benefiting numerous patients across India. However, the company now faces the challenge of addressing the GST demand while continuing its efforts in medical innovation and accessibility.